516 participants
A Clinical Study of JMT101 in Combination With Osimertinib Versus Osimertinib Alone as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Sensitive Mutations
- Study Type:
- INTERVENTIONAL
- Last Updated:
- 2024-12-16
- Start Date:
- 2024-10-23
- Completion:
- 2026-09-30
Conditions
- Locally Advanced or Metastatic Non-squamous NSCLC
- Harboring EGFR Sensitive Mutations NSCLC
- Previously Untreated Systematically NSCLC
Interventions
- DRUG
No Results Yet